In conclusion, our results identified a deregulated PRC1 component, CBX2 and established an association between CBX2, tumor progression, and resistance to DNA damage treatment, providing some evidence for future targeted therapy against CBX2 in cervical cancer. The gene discussed is PRC1; the disease is cervical cancer.